Home > Archive > 2016 >

Volume 35, Number 2 (May/June)

Integrating Point-of-care A1c Testing into a Comprehensive Diabetes Management Protocol: Insights from the Rio Grande Valley ACO (pages 8-11)

Rick San George, Ph.D., Vice President, Clinical Affairs, Alere

According to the International Diabetes Federation (IDF), 415 million people around the world currently live with Type 2 diabetes mellitus (T2DM). If current trends continue, the incidence of diabetes will rise to 642 million by 2040. The high cost of treatment due to complications and non-compliance contribute to the enormous burden T2DM places on the economic resources of the U.S. health-care system. Public health and medical organizations, therefore, recommend regular testing for people with T2DM to maintain glycemic control.
Management strategies and toolsHbA1c testing

SGLT-2 Inhibitors and DKA (pages 12-14)

Heather Saran and Kathleen Wyne, M.D., Ph.D.

Reports began emerging in 2015 of people with Type 1 diabetes (T1D) or Type 2 diabetes (T2D) developing euglycemic DKA while taking SGLT-2 inhibitors. They led to reviews of the class of medications by the U.S. Federal Drug Administration (FDA) and the European Medicines Agency (EMA). The American Association of Clinical Endocrinology held a consensus conference in October 2015 to discuss the clinical and scientific data.
Drug treatmentSodium-glucose cotransporter 2 inhibitors

Journal Watch (pages 15-19)

This column highlights recent clinical trial data and landmark clinical trials to provide readers with relevant information and links for obtaining clinical trial data and articles to facilitate discussion with patients and other providers. It features the results of four clinical trials: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) and ACCORDION A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results— A Long-term Evaluation (LEADER®) IMPACT-2: Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit.
Clinical trials

Traveling With Diabetes (pages 20)

You can take a holiday, but you must plan how to take your diabetes on holiday with you. Planning for travel with diabetes means you not only have to include medication and supplies on your packing list, but you also have to do some advance reading about your destination to plan for food and activity. Even a business trip requires advance planning, particularly if its duration might be extended.
Special activities with diabetesTraveling